Ghayas C. Issa

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Ghayas C. Issa
May 15, 2025, 13:36 | Science
Hagop Kantarjian: Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements
Hagop Kantarjian, Associate Vice President for Global Academic Programs at MD Anderson Cancer Center, shared…
Mar 11, 2025, 08:03 | Drugs
Naveen Pemmaraju: Bromodomain and PLX51107 with Azacitidine in Patients with R/R Myeloid Malignancies
Naveen Pemmaraju, Professor and Director of BPDCN Program at the Department of Leukemia at the University…
Jan 4, 2025, 15:18 | Insight
Vivek Subbiah: Top Phase 1 clinical trial publications of 2024
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA), shared…
Nov 4, 2024, 17:12 | Drugs
Talha Badar: Current FDA label for asciminib
Talha Badar, Hematologist at Mayo Clinic Comprehensive Cancer Center, shared a post on X: ''Deep dive…
Aug 12, 2024, 01:35 | Blog
Joshua Zeidner: Highly impactful data for R/R AML and menin inhibitors
Joshua Zeidner, Associate Professor at UNC Lineberger, shared a post by Ghayas Issa, Leukemia Physician at MD…
Jul 23, 2024, 22:30 | Blog
Hagop Kantarjian: The simultaneous combination of ponatinib and blinatumomab highly effective
Hagop Kantarjian shared on X: "The simultaneous combination of ponatinib and blinatumomab highly effective: MRD-negativity rate…
Jul 19, 2024, 13:19 | Insight
Sanam Loghavi: Optical genome mapping in acute myeloid leukemia
Sanam Loghavi, shared a post on X about a recent paper titled "Optical genome mapping improves…
All: 7 Posts: 1 - 100
Special Coverage